Spark Investment Management’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-5,041
Closed -$294K 108
2020
Q1
$294K Sell
5,041
-28,859
-85% -$1.86M 0.16% 191
2019
Q4
$2.71M Sell
33,900
-54,600
-62% -$4.09M 0.32% 97
2019
Q3
$6.5M Sell
88,500
-33,800
-28% -$2.92M 0.83% 20
2019
Q2
$11.5M Buy
122,300
+15,200
+14% +$1.25M 0.8% 24
2019
Q1
$8.57M Buy
107,100
+75,700
+241% +$5.59M 0.4% 74
2018
Q4
$1.69M Buy
31,400
+13,200
+73% +$802K 0.12% 225
2018
Q3
$1.42M Buy
+18,200
New +$1.26M 0.08% 323
2018
Q2
Sell
-19,000
Closed -$1.74M 662
2018
Q1
$1.74M Sell
19,000
-36,700
-66% -$3.16M 0.11% 249
2017
Q4
$4.2M Buy
55,700
+10,400
+23% +$732K 0.23% 138
2017
Q3
$3.16M Sell
45,300
-44,500
-50% -$2.38M 0.17% 197
2017
Q2
$4.55M Hold
89,800
0.28% 109
2017
Q1
$3.59M Sell
89,800
-2,100
-2% -$75.2K 0.23% 131
2016
Q4
$2.58M Sell
91,900
-85,400
-48% -$2.57M 0.21% 155
2016
Q3
$5.26M Buy
177,300
+32,800
+23% +$815K 0.43% 53
2016
Q2
$2.93M Buy
144,500
+58,800
+69% +$1.07M 0.27% 116
2016
Q1
$1.55M Buy
85,700
+76,000
+784% +$1.32M 0.16% 214
2015
Q4
$255K Buy
+9,700
New +$218K 0.03% 520

Other funds holding BPMC

Spark Investment Management's BPMC Position: Q2 2020 in Review

Spark Investment Management sold out of Blueprint Medicines (BPMC) in Q2 2020, closing a stake of 5,041 shares — an estimated $294K sold.

Spark Investment Management first reported a position in BPMC in Q4 2015 and held it in 17 quarters. The position peaked at $11.5M in Q2 2019. 235 funds tracked by Wall St. Rank hold BPMC as of Q2 2020.

  • Spark Investment Management reported no remaining Blueprint Medicines position as of Q2 2020 after selling out during the quarter.
  • Spark Investment Management sold 5,041 Blueprint Medicines shares in Q2 2020, an estimated $294K.
  • Spark Investment Management first reported a position in Blueprint Medicines in Q4 2015 and held it in 17 quarters.
  • Spark Investment Management's Blueprint Medicines position peaked at $11.5M in Q2 2019.
  • 235 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2020.

Based on Spark Investment Management's 13F filing for Q2 2020, filed 12 Aug 2020.